Otsuka's Voyxact Slows Kidney Decline to 3 Points/Year
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Otsuka disclosed results from a Phase 3 trial of its drug Voyxact in patients with IgA nephropathy.
- Voyxact‑treated patients showed an annualized eGFR decline of 3 points over one year.
- Placebo patients experienced an annualized eGFR decline of 7.6 points over one year.
- Voyxact’s effect, a 4.6‑point slower decline, was judged less than expected, leaving room for competing treatments.
Why it matters: Patients with IgA nephropathy get a 3‑point annual eGFR slowdown, but Otsuka’s modest benefit compared to 7.6‑point placebo opens market share for rival therapies in the US and Japan.
